-
Mashup Score: 2Assessing Oncologists’ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data - 1 year(s) ago
AbstractBackground. Despite national guideline recommendations for universal biomarker testing (KRAS, NRAS, BRAF, and mismatch repair and microsatellite instabi
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5E-health as a sine qua non for modern healthcare - 2 year(s) ago
In each era we need to balance between being able to provide care with our “technical skill, scientific knowledge, and human understanding” (Harrison’s Principles of Internal Medicine, 1950) to the individual patient and simultaneously ensure that our healthcare serves all. With the increasing demand of healthcare by an aging population and the lack of specialists, accessible healthcare within a…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
ASCO 2022 Real-World Treatment Patterns and Clinical Outcomes With 1L Therapy in Cisplatin-(In)eligible Patients With Advanced Urothelial Carcinoma
Source: VuMediCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report - 2 year(s) ago
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of all ovarian carcinomas. HGSOC harboring BRCA1/2 germline or somatic mutations are sensitive to the poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi). Therefore, detecting these mutations is crucial to identifying patients for PARPi-targeted treatment. In the clinical setting, next generation sequencing (NGS)…
Source: MDPICategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 5BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report - 2 year(s) ago
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of all ovarian carcinomas. HGSOC harboring BRCA1/2 germline or somatic mutations are sensitive to the poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi). Therefore, detecting these mutations is crucial to identifying patients for PARPi-targeted treatment. In the clinical setting, next generation sequencing (NGS)…
Source: MDPICategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 1
Scores of Covid vaccines are in development. Four companies have manufactured the majority of doses. But that doesn’t mean they are the best.
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Real-World Data & Technology Company OM1 Closes $85 Million Financing To Make Healthcare More Measured, Precise, And Pre-Emptive - 3 year(s) ago
/PRNewswire/ — OM1, a health technology company focused on real-world outcomes for chronic conditions, today announced an $85 million financing led by D1…
Source: www.prnewswire.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure - 3 year(s) ago
Importance Patient outcomes in heart failure clinical trials are generally better than those observed in real-world settings. This may be related to stricter inclusion and exclusion criteria in clinical trials. Objective We study sought to characterize the clinical implications of differences between patients in clinical trials and those in a real-world registry of patients receiving left…
Source: journals.plos.orgCategories: Cardiologists, Latest HeadlinesTweet
In this @JNCI_Now #CancerSpectrum article, Iyer et al investigate the #realworld outcomes in clinical practice settings of adherence to universal #biomarker testing as recommended across national #cancer guidelines. #precisionmedicine Read more here: https://t.co/BGyXNl1Vyh https://t.co/WKrRgus6go